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Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like 131I or 90Y still remains
ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of
90Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the
treatment output and toxicity when radionuclides such as 90Y, 177Lu, 131I, 124I, and 188Re are used. Tumour control probability (TCP)
and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed
with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses
were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed
uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). 90Y and 188Re are the best
candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the
radionuclide properties, high values of TCP can be reachedwithout toxicity if the number of radionuclides per nanoobject increases.
1. Introduction
Radioimmunotherapy uses radionuclides labelling of mon-
oclonal antibodies (mAbs) to deliver ionizing radiation to
tumour cells. Efficacy and toxicity of the treatment aremainly
influenced by the antibodies biokinetics and biodistribution
but also by radionuclides physical properties. Today, various
𝛽-emitters coupled to mAbs are being tested and compared
to eradicate tumour tissues. If this technique is well adapted
to treat radiosensitive hematopoietic malignancies, clinical
studies have always shown poor therapeutic effects on solid
and radioresistant tumours. Almost no clinical trials on
patients with colorectal, ovarian, gastric, pancreatic, prostate,
and breast cancer went beyond phase II [1]. This lack of
success might be partly explained by the fact that these solid
tumours are less sensitive to ionizing radiation and require
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doses larger than 60Gy to be sterilised [2]. Today, numer-
ous research studies are focused on optimizing radioim-
munotherapy by increasing the absorbed doses through a
better accumulation or a better penetration of radiolabelled
antibodies. But doses still remain insufficient to trigger a good
treatment response [3, 4].
Another solution to maximize the deposited doses inside
the solid tumour would be to increase the number of
radionuclides coupled to each antibody. Today, the coupling
is performed either by covalently binding the radionuclide
directly to the antibody or by crosslinking through a chelating
agent or chemical linker. These labelling procedures often
lead to a variable amount of radionuclides per antibody and
a too large number of radionuclides per mAb may impair
the antibodies immunoreactivity, leading to lower tumour
accumulation and higher liver uptake [5, 6].
To preserve immunoreactivity, one could imagine to
synthesize a nanoobject (NO) made of a nanoparticle (NP)
containing a large number of radionuclides, which is coupled
to each antibody. Indeed, it is now possible to assemble
nonradioactive and radioactive atoms to form radioactive
nanoparticles (NPs) [7–9]. In order to prevent their aggre-
gation and to maintain their stability within a biological
environment, the surface of these radioactive NPs can be
coated with polymeric macromolecules such as plasma poly-
merized allylamine (PPAA), polyethylene glycol (PEG), or
polysaccharide glycoprotein (Arabic gum) [10, 11]. These
types of macromolecules can also prevent radioactive atoms
from leaching. Moreover, NPs offer a large surface capable of
accommodatingmore than one antibody per particle,making
enhancement of uptake of these NPs inside or around the
tumour possible [11]. Another solutionwould be to synthesize
anotherNOmade of a biocompatible nanoparticle coupled to
more than one radiolabelled antibody. Experiments using this
kind of nanoobjects have recently shown that they could be
used for efficient cancer treatment. Indeed, in vivo imaging
on animals has proved that they are preferentially distributed
in the tumour mass after injection and that they present
an in vivo pharmacokinetic profile very similar to that of
uncoupled antibodies [12, 13].
In a first paper [14], absorbed doses (𝐷) deposited byNOs
made of antibodies coupled with nanoparticles containing
several 𝛽-emitters 90Y were simulated by using the Monte
Carlo particle transport code MCNPX (Monte Carlo N-
Particle eXtended). Dose values were calculated according to
a newmodel of spherical solid tumors inwhich the antibodies
could be distributed uniformly, linearly, or exponentially
inside the tumor volume. Preliminary results showed that
viable tumor cells received absorbed doses larger than 50Gy
everywhere inside the tumor. In a second paper, the good
therapeutic efficacy of these 90Y-NPs against non-small-
cell lung cancer (NSCLC) was theoretically confirmed by
determining the biological effective dose (BED) and tumor
control probability (TCP) [15]. NSCLC is a good example
of fast growing and radioresistant carcinoma with important
hypoxic areas. BED and TCP values took into account the
radiosensitivity of the targeted tissues, the doubling time of
the cancer cells, the repair process of sublethal damage taking
place between two irradiations, and the effect of hypoxia
for which the radiosensitivity changes according to whether
cells are anoxic or well-oxygenated. Early stage NSCLC is
usually treated surgically, although stereotactic body radia-
tion therapy (SBRT) may represent a good alternative when
inoperable [16–19]. Unfortunately, this fast growing tumour
is often diagnosed when already disseminated.
The main objective of this paper is to model the thera-
peutic efficacy and the complication risks of the surrounding
tissue when the NOs are filled with other 𝛽-emitters targeting
tumour cells. The assumption is that the NOs are well
targeting the metastases, but the energy deposition may be
influenced by the distribution inside the tumour deposits as
well as the NOs radioisotope concentration.
The first part of this paper will compare dose profiles for
five different 𝛽-emitters (90Y, 188Re, 177Lu, 124I, and 131I) to
see which one is the most efficient for treatment when only
one radionuclide is coupled to each antibody. The second
part is to establish, for the five different 𝛽-emitters, the
relationship between TCP and NTCP when the number of
radioactive atoms per NO varies. TCP and NTCP curves
were analyzed for three types of NO distributions (uniform,
linear, and exponential), with a tumoral biological half-life of
6 days and for two tumour sizes (0.5 cm and 1.0 cm radii).
For each TCP curve, the lowest number of radioactive atoms
per NO required to obtain a maximum TCP of 100% will be
determined, as well as the total doses deposited inside the
tumours and deposited in the surrounding tissues.
It has to be noted that it is not the intention of this paper
either to determine the amount of activity to administer to a
patient or to establish a treatment planning (for that purpose,
please see the review given by [20]). Instead, one has to
consider our results as advised to researchers who want to
develop NO-based radioimmunotherapy.
2. Material and Methods
For our simulations with the MCNPX software, the NSCLC
tumour is represented by a sphere subdivided into a set of
250 𝜇mradius spherical tumour cell clusters (TCCs) arranged
in a simple cubic lattice structure as represented in Figure 1
[15]. The surrounding lung tissue is described by a 4.0 cm
thick spherical shell also subdivided into small 250 𝜇m radius
spherical functional subunits (FSUs) also arranged in a cubic
lattice.The composition anddensity of each cell unit are taken
from ICRU-44 soft tissue for the TCCs and from ICRU-44
lung tissue for the FSUs.
For our geometric model, we also assume that the FSU
and TCC are surrounded by blood vessels which could be
either a new blood network created through angiogenesis
or simply the preexisting vasculature. Consequently the
radiolabelled antibodies or the radioactive nanoobjects can
penetrate within the lung tissues or the tumour and surround
the different cell units. So, the surface of each TCC and each
FSU becomes a potential source of radiation characterized
by a probability of emission. The latter will be similar for
all FSUs, meaning that the distribution of the NO in the
spherical shell is uniform. Inversely, for the tumour, the
probability of emission can be similar for all TCCs or can
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Figure 1: Three-dimensional representation of a NSCLC tumour
surrounded by lung shell. The tumour sphere is subdivided into
250 𝜇mdiameter spherical tumour cell clusters (TCCs) and the lung
shell is subdivided into 250 𝜇mdiameter functional subunits (FSUs).
decrease linearly and exponentially from the surface towards
the tumour centre. Finally, if the targeting function of the
antibodies is preserved, the TCC emission probability should
be higher than the FSU emission probability. According to
the experimental results given by Wiseman et al. [21], for
patients with non-Hodgkin’s lymphoma (NHL) treated with
90Y Zevalin, the mean tumour-to-lung deposited dose ratio
corresponded to 7, meaning that the doses absorbed by the
tumours are seven times higher than the doses deposited in
lung tissues. The mean tumour volume value was 42.5 cm3.
So, for our simulations, we have assumed that the TCC
emission probability is seven times more important than the
lung FSU emission probability.
In this work, the treatment of small NSCLC tumours
by RIT will be investigated for five different radionuclides
according to MCNPX simulations: one pure 𝛽-emitter (90Y),
two 𝛽-emitters with a low-abundance 𝛾 (177Lu and 188Re),
and two 𝛽-emitters with a higher 𝛾 abundance (131I and
124I). 131I is the most extensively used radionuclide in RIT
because of its availability, its ease for chemical conjugation,
and its ability to perform 𝛾 imaging and 𝛽 therapeutic
studies with the same biological vector. 131I- and 90Y-labelled
mAbs are mainly used to treat patients with NHL. However,
numerous phase I-II clinical trials have been reported for
patients with solid tumours [22]. Despite the high-energy 𝛽-
particles emitted by the 188Re, the clinical trials done with
this radionuclide only concern the treatment of patients with
haematological malignancies [23, 24]. Inversely, the efficacy
of the low-energy 𝛽-emitter 177Lu was only assessed to treat
solid tumours such as ovarian or prostate cancer [25–27].
More recently, numerous research studies into 124I have
been investigated because this high-energy positron-emitting
radionuclide is suitable for PET imaging and radioiodine
therapy [28, 29]. The main physical properties of these five
radionuclides are detailed in Table 1. 𝑇
1/2
phys is the physical
half-life of the five different radionuclides. 𝑝
𝛾
and 𝑝
𝑒
give,
respectively, the number of 𝛾 and electrons emitted per
disintegration. 𝐸
𝛾
is the energy of the main 𝛾 emission. 𝛾-
energies and emission probabilities for 177Lu, 188Re, 124I, and
131I were obtained from the website http://laraweb.free.fr/.
Positron emissions for 124I and their specific abundance
were taken from reference [30]. 𝐸
𝛽
represents the mean
energy of 𝛽-particles emitted per disintegration. The 𝛽-
spectra for the four different radionuclides were taken from
the database on the RADAR site (http://www.doseinfo-radar
.com/RADARDecay.html, October 2013). Finally, 𝑅
𝛽
gives
the mean 𝛽-particle range in soft tissues.
While 90Y is a pure𝛽-emitter, the four other radionuclides
emit photons which can also interact with the biological
matter inside the tumour to give birth to secondary electrons
or 𝛾 with smaller energies. The MCNPX code is capable of
studying the electron transport throughmatter by taking into
account the loss of energy, multiple scattering angles, and
“bremsstrahlung.” All these physical processes are considered
by using the photon-electron mode and the default PHYS
cards for electron and photons. When the different types of
radiations emitted per disintegration are taken into account,
the total absorbed dose to medium was determined by
formula (1) [31]:
𝐷 (𝑟) = 21.34 × 𝐸tot (𝑟) ×
1
𝜌
×
𝐴
𝜆eff
;
𝐸tot = (∑
𝑖
𝐸
𝑖
(𝑟) × 𝑝
𝑖
) ,
(1)
where 𝐸tot(𝑟) is the total deposited energy per unit of volume
and per disintegration for the different distances “𝑟” from the
tumour centre determined by using the SMESH tally from
MCNPX. This tally builds virtual concentric spherical shells
superimposed on the geometry of the tumour surrounded
by healthy lung tissues and defines the average energy, in
MeV/cm3, and per emitted particle (electron or gamma)
deposited into each shell located at different distances “𝑟”
from the tumour centre [14, 15]. The shell thickness chosen
for our simulations is 0.05 cm. For 188Re, 131I, 124I, and 177Lu,
𝐸tot(𝑟) was calculated by adding deposited energies, 𝐸𝑖(𝑟),
for 𝛾 and 𝛽 decays. The number of particle histories (NPS)
was chosen to obtain an energy deposition per shell volume
with a statistical uncertainty below 5% (1 SD). All physical
processes were taken into account by choosing the photon-
electron mode (MODE P E) and the default PHYS cards with
a lower cut-off value for electrons and photons at 0.005MeV.
𝑝
𝑖
are the total number of particles (electrons or gammas)
emitted per disintegration. Values of𝑝
𝑖
for𝛽 and 𝛾 decays and
for the different radionuclides are given in Table 1. The total
energy deposited in each spherical shell must still be divided
by the density (𝜌, in g/cm3) of the materials used to model
the tumour or its surrounding healthy tissue to obtain the
average energy per unit of mass and per emitted particle. 𝜆eff
is the effective decay constant, assuming a monoexponential
decay. This value is calculated by adding the physical decay
constant (𝜆phys = ln(2)/𝑇1/2
phys) and the biological clearance
4 Computational and Mathematical Methods in Medicine
Table 1: Physical characteristics of the different radionuclides studied in this work.
Nuclide 𝑇
1/2
phys (h) 𝑝
𝛾
𝐸
𝛾
(MeV) [abundance (%)] 𝑝
𝑒 𝐸𝛽 (MeV) 𝑅𝛽 (mm)
90Y 64.1 — — 1.0000 0.935 4
177Lu 161 0.1722 0.208 [6.1] 1.0000 0.133 0.26
124I 100 1.6380 0.603 [62.9] 0.2327 0.6860.974 4.1
131I 192 1.0980 0.365 [85.3] 1.0000 0.132 0.26
188Re 16.9 0.1981 0.155 [15] 1.0000 0.764 3.1
Table 2: Biological parameters used for TCP calculations for NSCLC tumour and healthy lung tissue.
Biological factors Tumour Healthy tissues
Tumoral tissues References Healthy tissues References
𝑇1/2bio [d] 2–6 [21] 3 [21]
𝛼/𝛽 [Gy] 10 [38], [34, 39, 40] 3 [38], [34, 39, 40]
𝜇 [h−1] 1.39 [38, 41] 0.46 [34, 38, 42]
𝛼 [Gy−1] 0.35 [39] 0.031 [43]
Cellular density [#/cm3] 9.5 × 107 [44] 9.5 × 107 [44]
rate constant (𝜆bio = ln(2)/𝑇1/2
biol). While the physical half-
life is well established (Table 1), the biological half-life of
the radiolabelled antibodies is more difficult to determine
(Table 2). The ratio A/𝜆eff represents the cumulated activity
by assuming an instantaneous antibody uptake and clearance
at a specific biological half-life𝑇bio.The total activity𝐴 inside
the tumours and surrounding healthy tissues is calculated
according to the following expression:
𝐴 = 𝜆phys × 𝑛𝑢 × 𝑛𝑎 × 𝑛mAb, (2)
where 𝑛
𝑢
represents the total number of cell clusters. 𝑛mAb
corresponds to the maximal number of radiolabelled mon-
oclonal antibodies capable of binding each cell cluster. Its
value is determined by multiplying the surface of the cell unit
by a mean 109mAb/cm2 covering fraction (surface antigen
concentration). The latter is defined as the number of bound
antibodies per tumour surface unit and its value usually varies
between 108 and 1010mAb/cm2 [32]. Finally, 𝑛
𝑎
is the number
of radioactive atoms per NO if direct uptake is assumed. 𝑛
𝑎
equals 1 if oneNO contains one single radioactive atom.Note,
however, that 𝑛
𝑎
in eachNO could be reduced by applying the
exponential radioactive decay law if we take into account that
several days (about 2 days) are usually required for antibody
maximum accumulation within the tumour [33].
To investigate how TCP and NTCP distributions evolve
with an increasing number of radionuclide contained in each
NO,𝐷(𝑟) is first converted into the biologically effective dose
BED(𝑟) according to formula (3) previously published and
based on the linear-quadratic model [15]:
BED (𝑟) = 𝐷 (𝑟) +
𝜆eff
(𝜆eff + 𝜇)
𝐷 (𝑟)2
𝛼/𝛽
, (3)
where 𝜇, in h−1, is the exponential rate constant quantifying
the rate of sublethal damage repair [34]. 𝛼 and 𝛽, expressed
in Gy−1 and Gy−2, respectively, are cellular radiosensitivities
determined from cell survival curves. All biological param-
eters required to determine TCP and NTCP are listed in
Table 2. They are assumed uniform throughout the NSCLC
tumour and the lung healthy tissues for our calculations.
TCP, defined as the probability that no tumour cell cluster
inside the NSCLC tumour survives irradiation, is obtained by
multiplying all the shell control probability values (SCP(𝑟))
from the tumour centre (𝑟 = 0) to the tumour surface (𝑟 = 𝑟
𝑇
)
TCP =
𝑟𝑇
∏
𝑟=0
SCP (𝑟) =
𝑟𝑇
∏
𝑟=0
(𝑝TCC (𝑟))
𝐾𝑟 , (4)
where SCP(𝑟) gives the probability that no tumour cell cluster
inside each spherical mesh located at a distance 𝑟 from the
tumour centre survives irradiation.𝐾
𝑟
is the number of TCC
within the concentric spherical shell located at a distance “𝑟”
from the tumour centre and 𝑃TCC is the probability to kill a
TCC determined by the Poisson expression:
𝑝TCC (𝑟) = exp {−𝑁Cells ⋅ exp {−𝛼TCC ⋅ BED (𝑟)}} , (5)
where 𝛼 is the tumour cell radiosensitivity and 𝑁Cells is the
number of tumour cells inside each TCC before irradiation
obtained by multiplying the density 𝜌 from Table 2 with the
TCC volume.
To assess the risk of pneumonitis after RIT treatment,
TCP curves will be compared to three different NTCP mod-
els. The first one is the phenomenological Lyman-Kutcher-
Burman (LKB) model expressed by
NTCPLKB =
1
√2𝜋
∫
𝑡
−∞
𝑒−𝑥
2
/2𝑑𝑥 with 𝑡 =
MLD − TD
50
𝑚 ⋅ TD
50
,
(6)
where TD
50
, in Gy, represents the dose for a 50% complica-
tion rate,𝑚 controls the NTCP curves slope, and MLD gives
the mean lung dose deposited into the pair of lungs. TD
50
and 𝑚 have never been determined for RIT. So we chose
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to use the values given by Seppenwoolde et al. for external
radiotherapy, that is, a TD
50
= 30.8Gy and𝑚 = 0.37 [35]. For
the MLD, we assumed that the dose deposited into a 4.0 cm
thick lung shell corresponded to the MLD deposited in both
lungs.
The secondNTCPmodel used in this paper for describing
the risk of pneumonitis a few months after treatment is the
relative seriality model (SER), initially proposed by Ka¨llman
et al. [36, 37]
NTCPSER = [1 − (1 − 𝑝
𝑠
FSU)
𝐾Lg]
1/𝑠
, (7)
where “𝑠” is the degree of seriality for the lung organ. Usually,
its value is close to zero with 𝑠 = 0.0061.𝐾Lg equals 76 394 192
and represents the total number of FSUs in the whole lung.
This value was obtained by dividing a mean lung volume of
5000 cm3 by the volume of one FSU. 𝑝FSU is the probability
of damaging one FSU, calculated with a similar expression to
(5), except that𝑁Cell is the number of cells in one FSU before
its irradiation and 𝛼 is the lung tissue radiosensitivity. 𝑁Cell
and 𝛼 are given in Table 2. BED(𝑟) in expression (5) will also
be replaced by a mean value of the BED within a 4.0 cm thick
lung spherical shell.
Finally, TCP curves will also be compared to a third
NTCP model for which a minimum number of FSUs (also
called tissue rescue units, TRUs) exist and maintain the
whole organ function. So, in this last model, we assume that
complication rises when all TRUs within the lungs are killed:
NTCPTRU
=
𝑟Lg
∏
𝑟>𝑟𝑇
exp {−𝑁TRU(𝑟) ⋅ exp {−𝛼FSU ⋅ BED (𝑟) ⋅ V
𝑐}} ,
(8)
where 𝑁
𝑟
gives the initial number of TRU in each spherical
shell located at a distance “𝑟” from the tumor center and
𝛼 describes FSU radiosensitivity; BED(𝑟) is the biological
effective dose at a distance “𝑟” from the tumour centre; 𝑐
reflects the volume effects; V is the fractional partial volume
defined by the ratio 𝑁tot/𝑁Lg (𝑁tot is the total number of
TRUs and 𝑁Lg is the number of TRUs within the pair of
lungs); 𝑁
𝑟
is the number of TRUs at a distance “𝑟” from the
tumour centre; 𝑟Lg is the distance from the tumor center of
the last spherical lung tumor shell, and 𝑐 = −0.98.
3. Results and Discussions
3.1. 𝐷(𝑟) and SCP(𝑟) Calculations When One Radionuclide Is
Labelled to Each Antibody. In this section, absorbed doses to
medium,𝐷(𝑟), and shell control probability, SCP(𝑟), as func-
tions of the distance “𝑟” from the tumour centre have been
compared for the five different radionuclides: 90Y, 177Lu, 131I,
124I, and 188Re. We assume here that only one radionuclide
is coupled to each antibody and that the five radionuclides
are separately conjugated to antibodieswith similar biological
properties, such as binding affinity, covering fraction, and
biological half-life. Results will be investigated to treat two
small NSCLC tumour sizes (0.5 and 1.0 cm radii) filled with
uniform, linear, or exponential antibody distribution. Rapid
and slow antibody clearances from the tumour are taken
into consideration by assuming two different biological half-
lives of 2 and 6 days. Tables 3 and 4 give the values of the
total doses (𝐷Tot), in Gy, absorbed by the 0.5 and 1.0 cm
radii tumours, respectively. These total absorbed doses were
obtained according to formula (1) for which the deposited
energy 𝐸
𝑖
(𝑟) was calculated with the MCNPX software by
considering a virtual sphere with a diameter equivalent to the
tumour size. Deposited doses in the centre (𝐷Cent) and at the
surface (𝐷Surf) of the NSCLC tumour were also presented in
these tables. 𝐷Lung represents the average dose deposited in
the 4.0 cm thick lung tissue shell around the tumour. This
value enables treatment impact assessment on the healthy
lung FSUs surrounding the tumour. By extension, we assume
that it is the average dose deposited in the whole organ. This
assumption probably overestimates the absorbed doses in
lungs because the highest doses in RIT aremainly localized in
the tumour vicinity. Finally, the three first columns of Tables
3 and 4 specify the type of radionuclide (Rad.), the shape of
antibody distribution (Dist.), and the activities (𝐴), in kBq,
calculated according to formula (2) with a mean covering
fraction of 109mAbs/cm2.
3.1.1. For 0.5 cm Radius Tumours. Doses deposited at dif-
ferent distances “𝑟” from the tumour centre for the five
different radionuclides and for the three possible antibody
distributions are represented in Figure 2 when the biological
half-life of the antibodies is set to 6 days. The highest values
for deposited doses are found in the tumour centre when
the antibody distribution is uniform, in the tumour middle
when the antibodies are distributed linearly, and near the
intratumoural surface for the exponential antibody distribu-
tion. Furthermore, due to the crossfire effect, the deposited
doses inside the tumour for a uniform distribution of 90Y-
and 188Re-labelled antibodies increase from the surface to
the tumour centre. Inversely, the plateau and the sharpness
of the falloff near the tumour surface for the absorbed dose
of 177Lu or 131I are due to shorter emission ranges in lung
tissues. As shown in Table 3, larger doses are deposited inside
the tumour for the five radionuclides when the time lapse
before the radiolabelled antibodies clearance increases.
The lowest values of the deposited doses inside the
tumour are located at the tumour surface or in the tumour
centre, depending on the radionuclide and the mAb dis-
tribution. If we look at Table 3, 𝐷Surf is lower than 𝐷Cent
when the five different radionuclides are distributed uni-
formly throughout the tumour, meaning that the minimum
deposited doses are found at the tumour surface. Inversely,
𝐷Cent is lower than 𝐷Surf when the radiolabelled antibodies
are distributed exponentially within the tumour. The situa-
tion is more complicated for linearmAb distribution. Indeed,
the minimum deposited doses are localized at the tumour
surface for high-energy 𝛽-emitters (90Y, 188Re, and 134I) and
in the tumour centre for low-energy 𝛽-emitters (131I and
177Lu).
Whereas strong variations of 𝐷Cent and 𝐷Surf appear
between the three different antibody distributions,𝐷tot seems
to remain constant for each radionuclide type. Consequently,
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Table 3: Comparison of the total absorbed dose (𝐷Tot), absorbed doses in the centre (𝐷Cent), and absorbed doses at the surface (𝐷Surf) or
surrounding the tumour (𝐷Lung), in Gy, when
90Y, 177Lu, 131I, 124I, and 188Re are separately linked to antibodies distributed uniformly, linearly,
and exponentially inside a 0.5 cm radius spherical tumour. Two different biological half-lives of 2 and 6 days are considered here.
Rad. Dist. 𝐴 [kBq] 𝐷Lung [Gy]
Absorbed dose [Gy]
𝑇
1/2
bio = 2 days 𝑇
1/2
bio = 6 days
𝐷Tot 𝐷Cent 𝐷Surf 𝐷Tot 𝐷Cent 𝐷Surf
90Y
Uni.
87.32
4.17 19.15 27.03 13.12 30.94 43.67 21.19
Lin. 4.18 18.41 18.69 13.98 29.75 30.20 22.59
Exp. 4.18 16.85 10.22 16.88 27.23 16.52 27.28
131I
Uni.
29.23
0.64 2.67 3.16 1.63 5.73 6.78 3.49
Lin. 0.64 2.65 1.65 1.91 5.68 3.55 4.10
Exp. 0.64 2.58 0.42 3.14 5.53 0.90 6.72
124I
Uni.
55.87
1.46 4.54 6.12 3.24 8.27 11.15 5.91
Lin. 1.46 4.39 4.17 3.47 8.00 7.60 6.32
Exp. 1.46 4.04 2.03 4.09 7.36 3.70 7.44
177Lu
Uni.
0.94
0.38 2.16 2.61 1.22 4.44 5.37 2.52
Lin. 0.38 2.15 1.18 1.50 4.43 2.43 3.09
Exp. 0.38 2.12 0.16 2.70 4.35 0.34 5.55
188Re
Uni.
34.78
5.22 28.87 40.32 19.15 34.90 48.74 23.15
Lin. 5.22 27.87 27.02 20.92 33.70 32.66 25.29
Exp. 5.23 25.49 12.90 26.05 30.82 15.60 31.49
Computed dose error is estimated to 5% (1 SD).
Table 4: Comparison of the total absorbed dose (𝐷Tot), absorbed doses in the centre (𝐷Cent), and absorbed doses at the surface (𝐷Surf) or
surrounding the tumour (𝐷Lung), in Gy, when
90Y, 177Lu, 131I, 124I, and 188Re are separately linked to antibodies distributed uniformly, linearly,
and exponentially inside a 1.0 cm radius spherical tumour. Two different biological half-lives of 2 and 6 days are considered here.
Rad. Dist. 𝐴 [kBq] 𝐷Lung [Gy]
Absorbed dose [Gy]
𝑇
1/2
bio = 2 days 𝑇
1/2
bio = 6 days
𝐷Tot 𝐷Cent 𝐷Surf 𝐷Tot 𝐷Cent 𝐷Surf
90Y
Uni.
684.13
3.84 22.2 29.8 11.7 35.8 48.1 18.9
Lin. 3.84 21.6 14.5 13.2 34.9 23.5 21.3
Exp. 3.87 18.9 0.78 20.8 30.6 1.26 33.5
131I
Uni.
228.29
0.60 2.67 3.06 0.97 5.73 6.55 2.09
Lin. 0.60 2.66 1.23 1.13 5.71 2.65 2.42
Exp. 0.60 2.61 0.31 2.43 5.60 0.67 5.20
124I
Uni.
436.97
1.35 5.14 6.36 3.02 9.36 11.58 5.51
Lin. 1.35 5.05 3.30 3.35 9.19 6.01 6.10
Exp. 1.35 4.56 1.11 5.08 8.31 2.02 9.25
177Lu
Uni.
222.32
0.36 2.07 2.25 0.53 4.26 4.63 1.09
Lin. 0.36 2.07 0.75 0.65 4.26 1.53 1.34
Exp. 0.36 2.06 0.03 1.73 4.24 0.05 3.55
188Re
Uni.
2609.61
4.83 32.0 40.9 16.2 38.7 49.5 19.6
Lin. 4.83 31.3 19.3 18.4 37.9 23.3 22.2
Exp. 4.86 27.9 0.54 31.0 33.8 0.65 37.5
Computed dose error is estimated to 5% (1 SD).
values of 𝐷tot strongly depend on the radionuclide choice
and not on the antibody distribution type. The largest 𝐷Tot
is given for 188Re-labelled antibodies. However, it does not
exceed 35Gy in the best conditions of treatment, that is, a
long biological half-life of 6 days and a uniform antibody
distribution throughout the tumour. Such a dose clearly
remains insufficient to treat 0.5 cm radius NSCLC tumours.
Figure 2 also shows values of SCP plotted against “𝑟” for
the five different radionuclides. These curves give a repre-
sentation of cell cluster-killing efficacy at different distances
“𝑟” from the tumour centre and give an idea about NSCLC
treatment output. For all types of antibody distributions,
SCP values for 177Lu, 124I, or 131I at different distances “𝑟”
from the tumour centre remain null, indicating that these
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Figure 2: Comparison of 𝐷(𝑟) and SCP(𝑟) profiles as a function of the distance “𝑟” from the tumour centre when single 90Y, 177Lu, 188Re,
131I, and 124I are coupled with antibodies distributed uniformly, linearly, and exponentially throughout a 0.5 cm radius tumour.The biological
half-life of antibodies within the tumour corresponds to 6 days.
three radionuclides are not adequate to treat this solid and
vascularized 0.5 cm radius tumour. By looking at the SCP
curves of 188Re and 90Y from Figure 2, we also see that the
spatial distribution of the antibodies plays an important role
in the treatment outcome. For biological half-lives of 2 or 6
days, 𝐷tot for uniform, linear, and exponential distribution
of 188Re-labelled antibodies is almost the same whereas the
shape of SCP curves varies strongly according to the type
of antibody distribution. A similar conclusion can be drawn
for 90Y-labelled antibodies. For both radionuclides, only a
small difference of about 3Gy is calculated between the total
doses deposited by the radiolabelled antibodies distributed
uniformly and exponentially, although strong differences
appear in the shape of SCP curves.The slight decrease of 5Gy
when antibody distribution becomes more heterogeneous is
explained by the fact that a part of the radiation is transferred
from the tumour surface into healthy tissues by crossfire
effects. However, with values lower than 3Gy for the different
radionuclides (cf. Table 3), doses deposited in healthy tissues
surrounding the tumour remain largely below the tolerated
mean radiation dose of 20Gy for the lung [35, 45].
3.1.2. For 1.0 cmRadius Tumours. Figure 3 presents deposited
doses, in Gy, for different radial distances when the biological
antibodies half-life is 6 days but this time we are studying
a 1.0 cm radius tumour. As previously observed for smaller
tumours of 0.5 cm radius, 𝐷Surf and 𝐷Cent strongly vary
with the radionuclide choice and the antibody distribution
type. For uniform distribution of radiolabelled antibodies,
maximal and minimal deposited doses are located in the
tumour centre and at the tumour surface, respectively. For
linear distribution, the highest deposited doses are found
between the tumour centre and the tumour surface. The
lowest deposited doses appear at the tumour surface, except
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Figure 3: Comparison of 𝐷(𝑟) and SCP(𝑟) profiles as a function of the distance ”𝑟" from the tumour centre when single 90Y, 177Lu, 188Re,
131I, and 124I are coupled with antibodies distributed uniformly, linearly, and exponentially throughout a 1.0 cm radius tumour.The biological
half-life of antibodies within the tumour corresponds to 6 days.
for the 124I which presents similar values for𝐷Cent and𝐷Surf.
Finally, deposited doses for exponential antibody distribution
are lower than 1Gy in the central part of the tumour and the
highest doses are deposited near the tumour surface. These
results still show that the shape of absorbed doses is strongly
affected by the antibody distribution type. Inversely, for each
radionuclide, very similar values for 𝐷tot and 𝐷Lung between
uniform, linear, and exponential antibody distributions are
given in Table 4. Only a small decrease of 𝐷tot appears when
the antibodies coupled with 90Y, 188Re, or 124I are distributed
exponentially rather than uniformly or linearly. Once again,
this decrease can be justified by a crossfire effect which causes
a radiation loss in the surrounding healthy tissues when the
antibodies are preferentially located at the tumour surface.
As shown in Table 4, the highest total deposited doses of
39Gy and 36Gy were calculated for 188Re- and 90Y-labelled
antibodies, respectively. However, these doses were obtained
according to a long biological half-life of 6 days and a good
penetration to generate a uniform activity distribution inside
the tumour. Note that a decrease of the antibody biological
half-life within the tumor can cause a decrease of𝐷tot within
the tumor. Higher total deposited doses are essential to
eliminate the NSCLC tumour, provided that these doses
remain lower than 20Gy in the surrounding healthy tissues.
For 90Y and 188Re, the largest doses deposited 4.0 cm beyond
the tumour surface remain lower than 20Gy, even with a
biological half-life of 6 days and an exponential distribution
of the antibodies.
As illustrated in Figure 3, SCP values for 131I, 124I, or
177Lu distributed uniformly, linearly, or exponentially equal
0% as previously observed for smaller 0.5 cm radius tumours.
Inversely, the shape of the SCP curves for 90Y and 188Re
radionuclides varies according to the antibody distribution
type. For a 𝑇bio of 6 days, SCP curves of
188Re-labelled anti-
bodies present a plateau starting from the tumour centre and
stopping before the tumour surface for uniform distribution,
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Table 5: Total absorbed dose (𝐷Tot), absorbed doses at the surface (𝐷Surf), and absorbed doses at the centre (𝐷Cent) or surrounding the
tumour (𝐷Lung), in Gy, required to obtain a maximum TCP of 100% when nanoobjects containing
90Y, 131I, 124I, 177Lu, and 188Re are coupled to
antibodies having a𝑇bio of 6 days and distributed uniformly, linearly, and exponentially inside a 0.5 cm radius spherical tumour.𝑁NO: number
of radioactive atoms per nanoobjects required for TCP = 100%.
Rad. Dist. 𝐴 [kBq] 𝑁NO Dose
Direct uptake 2 days of uptake 𝐷Tot [Gy] 𝐷Cent [Gy] 𝐷Surf [Gy] 𝐷Lung [Gy]
90Y
Uni. 370 2 4 77 108 52 10
Lin. 370 2 4 69 70 52 10
Exp. 370 3 5 79 48 79 12
131I
Uni. 370 15 18 88 104 54 10
Lin. 370 17 20 95 59 68 11
Exp. 1850 61 72 336 55 409 39
124I
Uni. 370 9 13 74 100 53 13
Lin. 370 8 12 67 64 53 12
Exp. 740 15 21 112 56 113 22
177Lu
Uni. 740 21 26 95 114 54 8
Lin. 740 26 33 117 64 82 10
Exp. 6660 188 232 820 63 1046 72
188Re
Uni. 740 2 15 72 101 48 11
Lin. 740 2 14 64 62 48 10
Exp. 1110 3 21 90 46 92 15
a large peak in the middle of the tumour for linear distribu-
tion, and a narrow peak near the tumour surface for expo-
nential distribution. Smaller and narrower SCP peaks appear
for the 90Y-labelled antibodies.This result suggests that 188Re-
radiolabelled antibodies have an increased chance of killing
NSCLC tumours, regardless of the mAbs distributions.
Consequently, when only one radionuclide is labelled to
each antibody, the highest tumour-to-lung deposited dose
ratios for both tumour sizes are achieved for low-energy 𝛽-
emitter 177Lu. However, the NSCLC treatment is favoured by
using high-energy 𝛽-emitters (90Y and, in particular, 188Re)
labelled to antibodies with a slow clearance (𝑇bio = 6 days)
and a good penetration (uniform distributions) within the
tumour.
3.2. TCP Results for Nanoobjects Containing More Than
One Radionuclide. Even with a covering fraction of
109mAbs/cm2, a long biological half-life of 6 days, and
a good intratumoural penetration of the radiolabelled
antibodies, results from Section 3.1 show that activity
remains insufficient to obtain total absorbed doses up to 60–
70Gy. The logical consequence is that all TCP values remain
null for both 0.5 cm and 1.0 cm radii tumours, regardless of
the radionuclide used for RIT treatment or the antibodies
biokinetics and spatial distribution. However, deposited
doses inside the tumour could be increased by synthesizing
nanoobjects containing more than one radionuclide per NO.
In this section, the impact on the therapeutic effectiveness
will be studied when the previously analysed radionuclides
coupled to each antibody are replaced by NO containing
more than one radioactive atom of 90Y, 177Lu, 131I, 124I,
and 188Re. For this purpose, the tumour control probability
(TCP) versus the number of radioactive atoms per NO will
be analysed. Its value represents the probability that a tumour
will be locally controlled for a given dose of radiation. A TCP
value of 0% implies that doses deposited inside the tumour
remain insufficient, while a TCP value of 100% predicts that
the tumour will be eradicated. Our TCP curves will then be
compared toNTCP values. Indeed, the latter limits our ability
to administrate the dose necessary to control the tumour.
Results reported in Tables 5 and 6 investigate how the
tumour size (0.5 and 1.0 cm radii) and the spatial distribution
of antibodies modify the number of radioactive atoms per
NO required for a maximum TCP of 100%. Both tables give
values of the total doses absorbed by the tumour (𝐷Tot, in
Gy), doses in the tumour centre (𝐷Cent, in Gy), and doses
deposited at the tumour surface (𝐷surf, in Gy), required to
have a TCP value of 100%. An increase in the deposited
doses inside tumours is often associated with an increase
in toxicity for healthy tissues surrounding the tumour. To
assess the negative effects these nanoobjects could have
on the surrounding healthy tissues in 4.0 cm thick shells
when TCP has reached 100%, the average doses deposited
beyond the tumour surface (𝐷Lung) are calculated for each
radionuclide. To avoid lung diseases like pneumonitis, it is
preferable that their values do not exceed the mean radiation
dose of 20Gy usually tolerated by healthy lung tissues.
The fourth and fifth columns in Tables 5 and 6 give the
number of radionuclides per antibody required to obtain
a TCP of 100%. These numbers are directly scaled with a
109mAbs/cm2 covering fraction and an antibody biological
half-life within the tumor of 6 days: a less specific antibody
with a covering fraction of 108mAb/cm2 would require the
number of radioactive atoms to be multiplied by ten to
obtain the same TCP. The fourth and fifth columns indicate,
respectively, the number of radionuclides when the uptake is
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Table 6: Total absorbed dose (𝐷Tot), absorbed doses at the surface (𝐷Surf), and absorbed doses in the centre (𝐷Cent) or surrounding the
tumour (𝐷Lung), in Gy, required to obtain a maximum TCP of 100% when nanoobjects containing
90Y, 177Lu, and 188Re are coupled with
antibodies having a𝑇bio of 6 days and distributed uniformly, linearly, and exponentially inside a 1.0 cm radius spherical tumour.𝑁NO: number
of radioactive atoms per nanoobjects required for TCP = 100%.
Rad. Dist. 𝐴 [kBq] 𝑁NO Dose
Direct uptake 2 days of uptake 𝐷Tot [Gy] 𝐷Cent [Gy] 𝐷Surf [Gy] 𝐷Lung [Gy]
90Y
Uni. 1850 3 5 106 142 56 11
Lin. 1850 3 4 92 62 56 10
Exp. 29600 43 73 1324 54 1450 167
131I
Uni. 6290 27 33 157 180 57 16
Lin. 5550 24 28 135 63 57 14
Exp. 19240 85 101 474 56 440 51
124I
Uni. 4440 10 14 96 119 57 14
Lin. 4070 9 13 86 56 57 13
Exp. 11470 26 36 216 52 240 35
177Lu
Uni. 14430 52 65 224 243 57 19
Lin. 11470 43 52 182 65 57 16
Exp. 271210 996 1224 4220 53 3539 362
188Re
Uni. 6660 3 19 101 129 51 13
Lin. 5920 2 16 87 54 51 11
Exp. 264920 102 726 3432 56 3805 494
supposed to be instantaneous (direct uptake) and the number
of radionuclides when 2 days are required to obtain the
maximum accumulation of radiolabelled antibodies within
the tumour after intravenous administration (2 days uptake)
[33]. For the treatment, it is evident that the more radioactive
atoms per NO are required, the more difficult the synthesis
of small size nanoparticles is. Finally, the three first columns
of these tables, respectively, specified the type of radionuclide
contained in the radioactive nanoobjects (Rad.), the type of
the antibody distribution (Dist), and the tumour activity (𝐴)
required to achieve a TCP of 100%.
3.2.1. For 0.5 cm Radius Tumours
𝐷
𝑡𝑜𝑡
for a TCP of 100%. For 90Y, 188Re, and 124I, a total
deposited dose lower than 110Gy inside the whole tumour
is sufficient to achieve a TCP of 100%. This value further
decreases when the antibodies are distributed linearly and
uniformly throughout the tumour until about 65 and 70Gy.
With 177Lu- or 131I-nanoobjects, doses required to completely
kill the tumour are higher for the three types of distribution.
The total deposited doses required for a TCP of 100%
remain unchanged when the biological half-life increases or
decreases but the number of radioactive atoms per NO is
different.The smaller the biological half-life is, the higher the
required number of radioactive atoms per NO is.
Independently of antibody distribution, 188Re and 90Y
require a lower number of radioactive atoms per NO to reach
a maximal TCP of 100%. Note that if a direct uptake was
assumed, the number of radionuclides per NO requested
for a TCP of 100% would be slightly larger for 188Re than
for 90Y despite a lower mean energy of 𝛽-particles emitted
by the 188Re. The situation is quite different if we consider
that 2 days are required to obtain a maximum accumulation
of radiolabelled antibodies within the tumour (column 5 in
Table 5). In this case, the number of 188Re per NO is higher
than the number of 90Y per NO due to the shorter physical
half-life of 188Re. Although the radionuclide 124I emits high-
energy positrons, the number of atoms per NO required to
achieve a TCPof 100% is larger compared to 90Yor 188Re.This
increase of atoms per NO can be explained by a lower num-
ber of 𝛽-particles emitted per disintegration (see Table 1).
Finally, 177Lu and 131I emit low-energy 𝛽-particles with a
range lower than the cell cluster diameter used for our tumour
model, meaning that the crossfire effects should be limited.
Consequently, the number of radionuclides perNOrequested
to reach a maximal TCP value of 100% drastically increases.
For all radionuclides, the exponential antibody distribution
requires a larger number of radioactive atoms per NO for
similar treatment efficacy.
𝐷
𝑆𝑢𝑟𝑓
and 𝐷
𝐶𝑒𝑛𝑡
for a TCP of 100%. For a NSCLC tumour
of 0.5 cm radius, we have previously shown that the lowest
deposited dose values inside the tumour are located at the
tumour surface or in the tumour centre, depending on anti-
body distribution, biological half-life, and the radionuclide
used for the treatment. As illustrated in columns 7 and
8 of Table 6, the minimum deposited doses for a TCP of
100% range from 46Gy to 64Gy. These results show that
a minimum deposited dose of about 55Gy everywhere inside
the tumour is required to obtain a good NSCLC treatment
outcome.
𝐷
𝐿𝑢𝑛𝑔
for a TCP of 100%. Treatment efficacy depends not
solely on the dose absorbed by the tumour but also on
the doses deposited by the nanoobjects in the surrounding
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healthy tissues. As observed in Table 6, average doses
deposited 4.0 cm beyond the tumour surface are lower
than 13Gy for the five different radionuclides distributed
uniformly and linearly through the tumour, meaning that
the nanoobjects should not have too many direct negative
effects on the healthy tissues surrounding the tumour. Larger
deposited doses in surrounding healthy tissues are calculated
for the exponential distribution of 131I-, 124I-, and 177Lu-
nanoobjects. This result is explained by the high number of
radionuclide per NO required for TCP = 100%.
Furthermore, the tumour-to-lung deposited dose ratios
(𝐷Tot/𝐷Lung) calculated for the five different radionuclides
and the three antibody distributions are similar to those
previously determined for a tumour when only one radionu-
clide is coupled to each antibody. So, the largest values for
the 𝐷Tot/𝐷Lung ratios are obtained for
177Lu-NPs, which
indicates that the treatment with 177Lu-NOs maximizes the
radiation dose to the tumour while minimizing normal
tissues irradiation. However, as the number of radioactive
atoms per NO is high and as 177Lu has a longer physical half-
life compared to 90Y and 188Re, it is very important to avoid
high concentrations of these 177Lu-nanoobjects accumulating
in the nontargeted normal organs. Indeed, one isolated NO
containing hundreds of atoms of 177Lu is harmless for the
patient but an accumulation of these nanoobjects in healthy
radiosensitive organs such as the red marrow may be very
dangerous.
TCP Curves. Figure 4 shows TCP curves, plotted for 0.5 cm
radiusNSCLC, in relation to the number of radioactive atoms
contained in each NO when a direct uptake is considered.
TCP curves are represented for the five radionuclides 90Y,
177Lu, 188Re, 131I, and 124I. For each radionuclide, the 3 types
of antibody distributions (uniform, linear, and exponential)
and for a biological half-life of 6 days were considered.
TCP curves differ according to the radionuclide used for
RIT and the type of antibody distribution, showing that
treatment efficacy depends on the choice of 𝛽-emitters but
also on the localization of the activity inside the tumour.
NTCP curves were added to assess the risk of pneumonitis
for RIT treatments. As illustrated in Figure 4, TCP curves
which appear the farthest to the left on each graph are
those for which the antibodies are distributed linearly or
uniformly through the tumour. Small differences appear
between these 2 distributions. When the nanoobjects are
distributed exponentially throughout the tumour, the TCP
curves shift to a higher number of radioactive atoms per NO.
However, for 90Y, 188Re, and 124I, a maximum TCP of 100%
could still be reached without toomany risks of pneumonitis.
Inversely, for the two low-energy 𝛽-emitters 131I and 177Lu, it
is impossible to apply an effective treatment without causing
strong lung complications. Indeed, TCP curves for both these
radionuclides in Figure 4 are predominantly located to the
right of the NTCP curves and tumour control without a
high incidence of complications is unlikely. Note that TCP
curves shift to the right when the biological half-life of the
antibodies decreases, allowing similar treatment efficacy with
a higher number of radionuclides per NO. The shift to the
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Figure 4: TCP values for a 0.5 cm radius tumour, calculated in %,
as a function of the number of radioactive atoms included in each
NO when the covering fraction corresponds to 1010 mAbs/cm2 and
𝑇bio = 6 days. TCP curves are represented for
90Y-NOs, 177Lu-NOs,
188Re-NOs, 131I-NOs, and 124I-NOs distributed uniformly, linearly,
and exponentially throughout the tumour. For each graph, TCP
curves are compared to NTCP curves to predict lung complications
risks.
right is even more pronounced when radionuclides have a
greater physical half-life such as 177Lu and 131I. Consequently,
for 124I-nanoobjects distributed exponentially within the
tumour, TCP and NTCP curves become too close to one
another to insure safe treatment if the antibody biological
half-life within the tumor decreases.
3.2.2. For 1.0 cm Radius Tumours
𝐷
𝑡𝑜𝑡
for a TCP of 100%. By comparing Table 6 with Table 5,
the total deposited doses to reach a maximum TCP of
100% are clearly higher when the tumour size increases. For
uniform and linear antibody distributions, the total deposited
doses for 124I, 188Re, and 90Y range from 86 and 106Gy
for a biological half-life of 6 days. Due to the low-energy
of 𝛽 emitted by 131I, a minimum 𝐷tot of 135Gy is required
to obtain a TCP of 100%. Such values can be explained by
the lack of crossfire effect which implies a higher difficulty
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to kill all the cell clusters located at the tumour surface.
With values larger than 180Gy, the total deposited dose
to achieve a TCP of 100% when antibodies are distributed
uniformly or linearly throughout the tumour still increases
for 177Lu, although this radionuclide has the same mean 𝛽-
particle range in soft tissues as 131I. When the antibodies
are distributed exponentially throughout the tumour, the
deposited doses required for a TCP of 100% greatly increase,
particularly for 90Y, 188Re, and 177Lu which require a 𝐷tot up
to, respectively, 1320Gy, 4220Gy, and 3430Gy. As previously
seen in Section 3.1, the minimum deposited dose for 90Y,
131I, 124I, 188Re, and 177Lu was located in the tumour centre
when antibodies are distributed exponentially throughout the
1.0 cm radius tumour. For the five radionuclides, doses in
the tumour centre range from 52 to 56Gy, meaning that a
minimum dose of about 55Gy is required everywhere inside
the tumour to achieve a TCP of 100%. So, the important
increase of 𝐷tot for the three radionuclides
90Y, 188Re, and
177Lu ismainly explained by the great difficulty to irradiate all
the cell clusters located in the tumour centre at about 55Gy.
Smaller increases of 𝐷tot are observed for
124I and 131I. This
probably results from the higher contribution of 𝛾 emissions
in the total deposited energy. Indeed, 𝛾-rays have a larger
range in soft tissues compared to 𝛽-particles and favour dose
depositions at a greater distance from the radionuclide. In
this way, all the cell clusters located in the tumour centre,
as well as those located at the tumour surface, are easier to
irradiate when the 124I- or 131I-nanoobjects are exponentially
distributed within the tumour.
For uniform and linear distributions of high-energy 𝛽-
emitters (90Y, 188Re, and 124I), the number of radionuclides
per NO does not really vary compared to smaller tumours
of 0.5 cm radius. The larger activities observed in Table 6
compared to Table 5 are essentially due to a larger number
of cell clusters around which the antibodies can be fixed. The
number of radionuclides needed to achieve a TCP of 100%
drastically increases when the 90Y- and 188Re-nanoobjects are
coupled to antibodies distributed exponentially throughout
the tumour. The strong activity increase calculated for expo-
nential antibody distribution comes from a larger number
of cell clusters within the tumour but also from a larger
number of radioactive atoms per NO. Such a result could be
explained by a great difficulty to irradiate all the cell clusters
localized in the tumour centre. Consequently, the exponential
distribution of both 188Re- and 90Y-nanoobjects represents
a disadvantage in the treatment of solid tumours with radii
equal to or larger than 1.0 cm.The latter problem is evenmore
striking when the low-energy 𝛽-emitter 177Lu is used for
internal radiation. Independently of the antibody distribution
type, the larger number of radionuclides per NO observed
when the tumour size increases could be explained by a great
difficulty to kill all the cell clusters located at the tumour
surface. A problem for irradiating cell clusters located in the
tumour centre also appears when antibodies are distributed
exponentially. Compared with 177Lu, the second low-energy
𝛽-emitter 131I seems to be less affected by this increase in the
tumour size. Indeed, the shift towards larger values for the
number of radionuclides per NO is smaller for 131I than for
177Lu. When the antibody distribution becomes exponential,
this number even appears lower than that of 188Re. Such
results are explained by a greater contribution of gamma rays
for 131I and show that, for ourMCNPX simulations, it is really
important to consider the total (𝛽 and 𝛾) energy deposition to
determine TCP values. A similar conclusion is reached for the
radionuclide 124I for which the lowest number of radioactive
atoms per NO required to get a good treatment output is
calculated when the antibody distribution is exponential.
𝐷
𝑆𝑢𝑟𝑓
and 𝐷
𝐶𝑒𝑛𝑡
for a TCP of 100%. For the three types of
antibody distributions, the minimum doses deposited in the
tumour centre or at the tumour surface are quite similar
to the results calculated for a 0.5 cm radius tumour. Their
values ranged from 51Gy to 57Gy, meaning that, once again,
a minimum value of 55Gy everywhere inside the tumour is
required to treat NSCLC correctly. To preserve such a dose in
the tumour centre when antibodies are distributed exponen-
tially throughout the 1.0 cm radius tumour, 𝐷Surf drastically
increases to doses larger than 1450Gy and 3800Gy for high-
energy 𝛽-emitters such as 90Y and 188Re, respectively. For
iodine radionuclides, 𝐷Surf decreases to lower values such as
240Gy for 124I and 440Gy for 131I.
𝐷
𝐿𝑢𝑛𝑔
for a TCP of 100%. For the 5 different radionuclides,
the deposited doses in the surrounding lung tissues are higher
than the values calculated for a 0.5 cm radiusNSCLC tumour,
independently of antibody distribution. However, for uni-
form and linear antibody distributions, 𝐷Lung remains lower
than 20Gy. When the antibodies are distributed exponen-
tially throughout a 1.0 cm radius NSCLC tumour, the doses
deposited in lung tissues are too high and NSCLC tumours
cannot be treated by a single injection of radiolabelled
antibodies. The best result is obtained for the 124I for which
doses in lung tissues reached 35Gy for a 6-day biological half-
life. The surrounding healthy tissues are less affected by the
radiation when the radioisotopes 177Lu, 124I, or 131I are used
despite a large amount of radioactive atoms per NO required
for a TCP of 100%.However, the synthesis of nanoobjects able
to assemble such an important number of radioactive atoms
remains very difficult experimentally. Furthermore, this high
number of radionuclides, mixed with other nonradioactive
organic or inorganic atoms and surrounded by additional
macromolecules, could formnanoobjects too large to prevent
uptake by the reticuloendothelial system and to promote their
diffusion throughout the target tissue.This problemwould be
even more important if the covering fraction is decreased.
TCP Curves. To analyze how tumour size may influence
the number of radioactive atoms per antibody required to
maximize the treatment efficacy, TCP distributions have
been plotted for 1.0 cm radius tumours. In Figure 5, TCP
versus the number of radioactive atoms is represented for
the five different radionuclides 90Y, 177Lu, 131I, 124I, and
188Re distributed uniformly and nonuniformly throughout
the tumour. As previously stated, a biological half-life of 6
days for antibodies located inside the tumourwas considered.
Firstly, we can see that uniform and linear distributions of
Computational and Mathematical Methods in Medicine 13
0 40 80 120 160 200 240 280 320 360 400
0 2 4 6 8 10 12 14 16
0 10 20 30 40 50 60 70
0 5 10 15 20 25
0 20 40 60 80 100 120 140 160
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
TC
P 
or
 N
TC
P
TC
P 
or
 N
TC
P
TC
P 
or
 N
TC
P
TC
P 
or
 N
TC
P
TC
P 
or
 N
TC
P
Number of radioactive atoms per nanoobject
90Y
124I
177Lu
131I
188Re
Uniform
Linear
Exponential
NTCPLKB
NTCPSER
NTCPTRU
Figure 5: TCP values for a 1.0 cm radius tumour, calculated in %,
as a function of the number of radioactive atoms included in each
NO when the covering fraction corresponds to 1010mAbs/cm2 and
𝑇bio = 6 days. TCP curves are represented for
90Y-NOs, 177Lu-NOs,
188Re-NOs, 131I-NOs, and 124I-NOs distributed uniformly, linearly,
and exponentially throughout the tumour. For each graph, TCP
curves are compared to NTCP curves to predict lung complications
risks.
90Y-, 124I-, or 188Re-nanoobjects from Figure 5 are almost
similar in shape and location as those plotted in Figure 4
for smaller tumours. Consequently, tumour size does not
influence treatment efficacy. Inversely, TCP curves when
the 90Y- and 188Re-nanoobjects are coupled to antibodies
distributed exponentially throughout a 1.0 cm radius tumour
are to the right of those for complications, whereas those
for smaller tumours are to the left. Note that TCP curves
are localized too far away from the left of the NTCP curves
to be plotted on Figure 5. Even if the shift to the right
is less important for the 124I-NPs radiolabelled antibodies
distributed exponentially throughout the tumour, maximal
TCP could not be reached without lung complications.
By comparing Figure 4 with Figure 5 for both low-energy
𝛽-emitters 131I and 177Lu, TCP curves for uniform and
linear distributions shift to the right whereas NTCP curves
remain unchanged when the tumour size increases.This shift
towards higher numbers of radionuclides still increases when
the biological half-life decreases, meaning that the risk of
pneumonitis increases.
To conclude, the tumour-to-lung deposited dose ratios
for both tumour sizes are similar to those obtained when
only one radioactive atom is attached to each antibody.
So, the highest 𝐷Tot/𝐷Lung is calculated for the
177Lu-NO,
independently of the antibody distribution or tumor size.
However, after TCP and NTCP analyses, 90Y and 188Re seem
the best candidates for the treatment of NSCLC tumourwhen
antibodies are distributed uniformly or linearly. For expo-
nential antibody distribution, the radionuclide 124I becomes
amore adequate candidate, especially for tumours equal to or
larger than 1.0 cm radius.
4. Conclusion
This work presents the tumour control probability analysis
for solid tumours when nanoobjects (e.g., radiolabelled mAB
or mAb bioconjugated nanoparticle) contain one or several
𝛽-emitters which could be used in radioimmunotherapy.
NSCLCwas selected as tumourmodel as its biological param-
eters are well reported in literature. TCP and NTCP were
calculated according to tumour and normal surrounding
tissue deposited doses resulting from MCNPX, a Monte
Carlo electron, and photon and particles transport code.
Dosimetric studies were performed for the five radioisotopes
90Y, 177Lu, 131I, 124I, and 188Re, for two spherical tumour
sizes of 0.5 and 1.0 cm radii and for two biological half-lives.
Moreover, these nanoobjects can be distributed uniformly,
linearly, or exponentially throughout the tumours according
to a new vascularized tumourmodel previously developed for
MCNPX.
When nanoobjects contain only one radionuclide, sim-
ulations show that the dose absorbed by the solid tumour
is insufficient for solid tumour treatment, regardless of the
radionuclide used for RIT treatment or the biokinetics and
spatial distributions of antibodies; even so 188Re and 90Y show
the highest deposited doses within the solid tumour.
Higher total absorbed doses can easily be achieved
when single radionuclides radiolabelled-mAbs are replaced
by nanoobjects containing several 𝛽-emitters. The required
number of atoms per nanoobject to get TCP = 100% changes
according to numerous radionuclide physical properties such
as the physical half-life, abundance of 𝛾 emissions, and
energies of the emitted 𝛽-particles and 𝛾 particles, but also
according to the biological properties of the nanoobjects
such as their concentration inside the tumour, their spatial
distribution, or their biological half-life. These results con-
firm the importance of performing individual treatment for
each patient. The total absorbed doses to obtain excellent
tumour control vary between 60Gy and more than 5000Gy
depending on the radionuclide choice, tumour size, and
nanoobjects spatial distribution. 90Y and 188Re are the choice
if one wants to minimize the number of radioisotopes per
nanoobject.
Finally, higher absorbed doses are often synonymouswith
higher toxicity. Consequently, NTCPusually limits our ability
to administer the doses required to control the tumour. For
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small 0.5 cm radius tumours, simulations do not show any
toxicity problems. In this case, 90Y and 188Re remain the
best candidates because they require the lowest number of
radionuclides per nanoobject to reach a TCP of 100%. On the
other hand, for larger 1.0 cm radius tumours, toxicity to the
surrounding healthy tissue is observed when the nanoobjects
are distributed exponentially throughout the tumour. This
toxicity increases strongly for high-energy𝛽-emitters and 124I
becomesmore appropriate to cure solid tumours. Such results
indicate the importance of finding new strategies to insure the
penetration of nanoobjects inside tumours.
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